Weaponizing chitosan and its derivatives in the battle against lung cancer.
Int J Biol Macromol
; 272(Pt 2): 132888, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38844273
ABSTRACT
Lung cancer (LC) is a crisis of catastrophic proportions. It is a global problem and urgently requires a solution. The classic chemo drugs are lagging behind as they lack selectivity, where their side effects are spilled all over the body, and these adverse effects would be terribly tragic for LC patients. Therefore, they could make a bad situation worse, inflict damage on normal cells, and inflict pain on patients. Since our confidence in classic drugs is eroding, chitosan can offer a major leap forward in LC therapy. It can provide the backbone and the vehicle that enable chemo drugs to penetrate the hard shell of LC. It could be functionalized in a variety of ways to deliver a deadly payload of toxins to kill the bad guys. It is implemented in formulation of polymeric NPs, lipidic NPs, nanocomposites, multiwalled carbon nanotubes, and phototherapeutic agents. This review is a pretty clear proof of chitosan's utility as a weapon in battling LC. Chitosan-based formulations could work effectively to kill LC cells. If a researcher is looking for a vehicle for medication for LC therapy, chitosan can be an appropriate choice.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Quitosana
/
Neoplasias Pulmonares
/
Antineoplásicos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Int J Biol Macromol
/
Int. j. biol. macromol
/
International journal of biological macromolecules
Ano de publicação:
2024
Tipo de documento:
Article